Table of Content



1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Treatment Type
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics
4.1. Impacting Factors
4.1.1. Driver
4.1.1.1. Increasing prevalence of virus-associated pericarditis
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. Side effects of pericardiectomy
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis

5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regional Analysis
5.5. Regulatory Analysis
5.6. DMI Opinion

6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Acute Pericarditis*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Incessant Pericarditis
7.4. Chronic Pericarditis
7.5. Others

8. By Treatment Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Drug*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.2.1. Pain Relievers
8.2.2.1.1.1. Aspirin
8.2.2.1.1.2. Ibuprofen
8.2.2.2. Anti-inflammatory drugs
8.2.2.2.1.1. Colchicine
8.2.2.2.1.2. Corticosteroids
8.2.2.2.1.3. Others
8.3. Procedure
8.3.1.1. Pericardiocentesis
8.3.1.2. Pericardiectomy
8.3.1.3. Others

9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals and Clinics*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cardiac Centers
9.4. Others

10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles
12.1. Teva Pharmaceuticals USA, Inc.
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Par Pharmaceutical
12.3. Merck KGaA
12.4. Cumberland Pharmaceuticals Inc.
12.5. Johnson & Johnson Inc.
12.6. Bayer AG
12.7. Midas Pharma GmbH.
12.8. Alchem International Pvt. Ltd.
12.9. Takeda Pharmaceutical Company Limited
12.10. Azure Pharmaceuticals
LIST NOT EXHAUSTIVE

13. Appendix
13.1. About Us and Services
13.2. Contact Us